| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Aprea's WEE1 inhibitor shows disease stabilization in early trial | 1 | Investing.com | ||
| APREA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 | 93 | GlobeNewswire (Europe) | 3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in... ► Artikel lesen | |
| Fr | Aprea Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.10. | Aprea sets 1,100 mg dose for ATR inhibitor, shifts focus to combinations | 1 | Investing.com | ||
| 15.10. | Aprea Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.09. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | Aprea Therapeutics GAAP EPS of -$0.53 | 1 | Seeking Alpha | ||
| 12.08. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update | 164 | GlobeNewswire (Europe) | Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor... ► Artikel lesen | |
| 12.08. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.06. | Aprea Therapeutics: Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with ... | 127 | GlobeNewswire (Europe) | Preclinical data demonstrate potent single-agent and combination effects in head and neck squamous cell carcinoma (HNSCC) models, including synergy with anti-PD-1 therapy Initial Phase 1 clinical... ► Artikel lesen | |
| 09.06. | Aprea Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Aprea Therapeutics GAAP EPS of -$0.66 | 1 | Seeking Alpha | ||
| 14.05. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update | 135 | GlobeNewswire (Europe) | ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial ... ► Artikel lesen | |
| 14.05. | Aprea Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.03. | Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | 198 | GlobeNewswire (Europe) | ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119... ► Artikel lesen | |
| 11.03. | Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) | 188 | GlobeNewswire (Europe) | DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen | |
| 11.12.24 | Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward | 267 | GlobeNewswire (Europe) | Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,972 | +1,54 % | Rheinmetall: Ziel 1.500 Euro? - BYD, Circus, Evotec, Novo Nordisk und stock3 im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| BB BIOTECH | 43,150 | +4,48 % | BB Biotech profitiert von Erfolgen im Portfolio | Schaffhausen - Die Beteiligungsgesellschaft BB Biotech hat im dritten Quartal mit 448 Millionen Franken einen hohen Gewinn erzielt, nach Verlusten in den beiden Quartalen davor. Nebst einem verbesserten... ► Artikel lesen | |
| CUREVAC | 4,592 | -0,65 % | BioNTech startet milliardenschweres Umtauschangebot für CureVac-Aktien | BioNTech hat das öffentliche Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. gestartet. Das Angebot basiert auf dem Kaufvertrag vom 12. Juni 2025 und sieht vor, dass jede CureVac-Aktie... ► Artikel lesen | |
| VALNEVA | 4,108 | +0,49 % | Valneva-Aktie vor entscheidendem Tag - darauf kommt es jetzt an! | ||
| BIOGEN | 129,30 | +0,35 % | Biogen Inks License Deal For Vanqua Bio's Oral C5aR1 Antagonist | WESTON (dpa-AFX) - Biogen Inc. (BIIB), Friday announced a license agreement granting the company exclusive worldwide rights to Chicago-based Vanqua Bio's preclinical, oral C5aR1 antagonist,... ► Artikel lesen | |
| ILLUMINA | 86,77 | +0,81 % | Biotech-Wende: Nach 4 Jahren Crash: Illumina-Aktie vor massivem Kaufsignal | Die Aktie des Krebsforschungsspezialisten Illumina steckt seit Jahren in einem Abwärtstrend. Doch nun mehren sich die Anzeichen für eine Trendwende. Die Aktie hat die Mehrjahrestiefs hinter sich gelassen... ► Artikel lesen | |
| ABIVAX | 78,50 | +0,64 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| GINKGO BIOWORKS | 11,600 | -0,85 % | Dr. Dennis Riedl: Diese Aktie hat es in sich: Riedls Biotech-Wette auf zelluläre Landwirtschaft | ||
| ONCO-INNOVATIONS | 0,815 | +3,16 % | Onco-Innovations Limited: Onco-Innovations Announces Private Placement | Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / October 14, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H... ► Artikel lesen | |
| NUVALENT | 93,39 | +2,75 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,405 | +0,32 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 66,06 | -3,25 % | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | ||
| INHIBRX BIOSCIENCES | 57,29 | +102,01 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARVINAS | 9,210 | +0,66 % | Arvinas reports promising preclinical data for KRAS G12D cancer drug | ||
| NEUPHORIA THERAPEUTICS | 6,260 | +55,34 % | Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings | BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |